Last reviewed · How we verify
Ongentys
At a glance
| Generic name | Ongentys |
|---|---|
| Sponsor | Bial - Portela C S.A. |
| Target | Catechol O-methyltransferase, Catechol O-methyltransferase |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Parkinson's disease
Common side effects
- Dyskinesia
- Constipation
- Blood creatine kinase increased
- Hypotension/Syncope
- Weight decreased
Serious adverse events
- Fall
- Confusional state
- Hallucinations and Psychosis
- Impulse Control/Compulsive Disorders
Key clinical trials
- A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD (PHASE4)
- Opicapone Treatment Initiation Open-Label Study
- Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease
- Relative Bioavailability and Bioequivalence of Opicapone (PHASE1)
- Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC) (PHASE1)
- Efficacy and Safety of Opicapone in Clinical Practice (PHASE4)
- Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone (PHASE1)
- Effect of Food on Opicapone (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ongentys CI brief — competitive landscape report
- Ongentys updates RSS · CI watch RSS
- Bial - Portela C S.A. portfolio CI